Your browser doesn't support javascript.
loading
Osteoporosis and Low Bone Mineral Density in Men with Testosterone Deficiency Syndrome.
Gaffney, Christopher D; Pagano, Matthew J; Kuker, Adriana P; Stember, Doron S; Stahl, Peter J.
Afiliação
  • Gaffney CD; College of Physicians and SurgeonsColumbia University Medical CenterNew YorkNYUSA.
  • Pagano MJ; Department of UrologyColumbia University Medical CenterNew YorkNYUSA.
  • Kuker AP; Division of EndocrinologyDepartment of MedicineColumbia University Medical CenterNew YorkNYUSA.
  • Stember DS; Department of UrologyIcahn School of Medicine at Mount SinaiNew YorkNYUSA.
  • Stahl PJ; Department of UrologyColumbia University Medical CenterNew YorkNYUSA. Electronic address: ps2192@cumc.columbia.edu.
Sex Med Rev ; 3(4): 298-315, 2015 Oct.
Article em En | MEDLINE | ID: mdl-27784602
INTRODUCTION: Testosterone deficiency syndrome (TDS) is a risk factor for low bone mineral density (BMD) and osteoporosis. Knowledge of the relationship between TDS and bone health, as well as the practical aspects of how to diagnose and treat low BMD, is therefore of practical importance to sexual medicine practitioners. AIM: The aim of this study was to review the physiologic basis and clinical evidence of the relationship between TDS and bone health; and to provide a practical, evidence-based algorithm for the diagnosis and management of low BMD in men with TDS. METHODS: Method used was a review of relevant publications in PubMed. MAIN OUTCOME MEASURES: Pathophysiology of low BMD in TDS, morbidity, and mortality of osteoporosis in men, association between TDS and osteoporosis, indications for dual X-ray absorptiometry (DXA) scanning in TDS, evidence for testosterone replacement therapy (TRT) in men with osteoporosis, treatment for osteoporosis in the setting of TDS. RESULTS: Sex hormones play a pleomorphic role in maintenance of BMD. TDS is associated with increased risk of osteoporosis and osteopenia, both of which contribute to morbidity and mortality in men. DXA scanning is indicated in men older than 50 years with TDS, and in younger men with longstanding TDS. Men with TDS and osteoporosis should be treated with anti-osteoporotic agents and TRT should be highly considered. Men with osteopenia should be stratified by fracture risk. Those at high risk should be treated with anti-osteoporotic agents with strong consideration of TRT; while those at low risk should be strongly considered for TRT, which has a beneficial effect on BMD. CONCLUSION: Low BMD is a prevalent and treatable cause of morbidity and mortality in men with TDS. Utilization of a practical, evidence-based approach to diagnosis and treatment of low BMD in men with TDS enables sexual medicine practitioners to make a meaningful impact on patient quality of life and longevity. Gaffney CD, Pagano MJ, Kuker AP, Stember DS, and Stahl PJ. Osteoporosis and low bone mineral density in men with testosterone deficiency syndrome.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2015 Tipo de documento: Article